Cellular senescence is a complex tumor-suppressive mechanism induced by many different stresses. Senescent cells are characterized by growth arrest, changes in morphology and gene expression, and the secretion of inflammatory cytokines, proteases and other molecules that can alter the tissue microenvironment (a phenomenon termed the senescence-associated secretory phenotype or SASP). For an unknown mechanism, senescent cells increase with age, and are evident at sites of numerous age-related pathologies and pre-cancerous lesions. Recent results show that life-long elimination of senescent cells can prevent the development of certain age-related pathologies in a mouse model of segmental accelerated aging, strongly supporting the idea that senescent cells can be deleterious. In contrast, we and others have shown that the SASP might have a beneficial effect during tissue repair by promoting collagen degradation and differentiation of myofibroblasts. Thus, there is the possibility that senescence has been selected to ensure early life fitness (wound healing), but may have unselected deleterious effects late in life (aging and cancer promotion).
The Demaria lab is interested to dissect the molecular phenotypes of cellular senescence induced by different stimuli, and to characterize how they can promote age-related cancers.
The proposed project aims to determine how senescent cells are accumulated upon UV radiation, and the contribution of UV-induced senescence for melanoma progression. More in the specific, we will use different mouse models, mouse and human primary cells and human biopsies. We will evaluate the induction and the behaviour of senescent cells induced by UV, and their pro-tumorigenic phenotype in relation to melanoma. Moreover, we will screen and test different compounds with the potential of specifically eliminate senescent cells in vivo. You will study gene expression, cellular interactions, immune cell activation, melanomagenesis, tumor progression, drug actions and phenotypic effects.
The Postdoc will be part of a young and enthusiastic research group and should have the following requirements:
- Required education/skills: PhD in Molecular/Medical Biology
- Experience in a wide variety of molecular and cellular biology techniques (e.g. qPCR, FACS, Western blots, histology, cell culture)
- Excellent record of work with mice and cancer models
- Should be enthusiastic, ambitious, and organized
- Collaborative, communication and networking skills are mandatory
- Good knowledge of English
The UMCG has a preventive Hepatitis B policy. The UMCG can provide you with the vaccination, should it be required for your position.
Employment basis: 1,0 fte - 36 hours / week), temporary for specified period
Duration of the contract: One year with possibility for extension (funding available for three years)
Maximum salary amount: € 4.216,- (scale 10) gross per month depending on your qualifications and experience, based on a fulltime position. In addition, the UMCG will offer you 8% holiday pay, an 8.3% end-of-year bonus and a development budget.
The terms of employment comply with the Collective Labour Agreement for Medical Centers (CAO-UMC).
For more information see www.eriba.umcg.nl
or contact Dr. Marco Demaria, team leader of the laboratory, email: email@example.com
((please do not use e-mail adres for applications).
Full applications including a motivation letter, your resume and two contacts for reference letters will receive full consideration.
ERIBA websiteUMCG Corporate information/researchWelcome to Groningen